根據(jù)一項新的研究，利用人干細(xì)胞,，研究人員開發(fā)出一種促進(jìn)紅細(xì)胞產(chǎn)生的新方法。他們的發(fā)現(xiàn)能夠顯著性地增加輸血時所需的血液供應(yīng),，而且他們的方法也能夠被用來生產(chǎn)任何血型的血液,。
美國紐約市阿爾伯特愛因斯坦醫(yī)學(xué)院研究員Eric Bouhassira說，“我們將不同的細(xì)胞增殖技術(shù)綜合在一起,，從而能夠10到100倍地增加紅細(xì)胞產(chǎn)生的數(shù)量,。”
當(dāng)前,，用于拯救生命的輸血所需的血液只能通過捐血來獲得。因此,，血液能夠出現(xiàn)短缺,，特別是那些罕見血型的血液。研究人員利用來自臍帶血和循環(huán)血液中的干細(xì)胞和胚胎干細(xì)胞來更加高效地產(chǎn)生紅細(xì)胞,。
Bouhassira說,，“科學(xué)家們規(guī)模化工業(yè)生長大量紅細(xì)胞的能力可能在輸血醫(yī)學(xué)域領(lǐng)引發(fā)一場變革,。通過基于捐血的系統(tǒng)的血液收集雖然能夠很好地為我們服用,，但是它的成本較高，容易遭受破壞,，而且不足以滿足一些需要進(jìn)行輸血的人們的需求,。(這項研究中開發(fā)出的)方法可能是一個不錯的長期替代選擇。”
2012年8月2日,，相關(guān)研究結(jié)果在線發(fā)表在Stem Cells Translational Medicine期刊上,。(生物谷：Bioon.com)
本文編譯自Study uses stem cells to boost red blood cell production
doi: 10.5966/sctm.2012-0059
PMC:
PMID:
Novel, High-Yield Red Blood Cell Production Methods from CD34-Positive Cells Derived from Human Embryonic Stem, Yolk Sac, Fetal Liver, Cord Blood, and Peripheral Blood
Emmanuel Olivier, Caihong Qiu and Eric E. Bouhassira
The current supply of red blood cells expressing rare blood groups is not sufficient to cover all the existing transfusion needs for chronically transfused patients, such as sickle cell disease homozygous carriers, because of alloimmunization. In vitro production of cultured red blood cells is slowly emerging as a possible complement to the existing collection-based red blood cell procurement system. The yield of cultured red blood cells can theoretically be maximized by amplifying the stem, progenitor, or precursor compartment. Here, we combined methods designed to expand these three compartments to optimize the yield of cultured red blood cells and found that exposing CD34+ cells to a short pulse of cytokines favorable for erythroid differentiation prior to stem cell expansion followed by progenitor expansion produced the highest yield of erythroid cells. This novel serum-free red blood cell production protocol was efficient on CD34+ cells derived from human embryonic stem cells, 6–8-week yolk sacs, 16–18-week fetal livers, cord blood, and peripheral blood. The yields of cells obtained with these new protocols were larger by an order of magnitude than the yields observed previously. Globin expression analysis by high-performance liquid chromatography revealed that these expansion protocols generally yielded red blood cells that expressed a globin profile similar to that expected for the developmental age of the CD34+ cells.
